天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ChemicalBook >> journal list >> Drugs >>article
Drugs

Drugs

IF: 13
Download PDF

Letermovir: First Global Approval.

Published:1 January 2018 DOI: 10.1007/s40265-017-0860-8 PMID: 29288370
Esther S Kim

Abstract

Letermovir (Prevymis?) is an orally or intravenously administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc., under a global license from AiCuris Anti-infective Cures GmbH. Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant (HSCT). In addition, letermovir has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, and is under review in several countries, including Japan. This article summarizes the milestones in the development of letermovir leading to its first global approval in Canada as well as the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic HSCT.

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
LeterMovir 917389-32-3 C29H28F4N4O4 219 suppliers $15.00-$1680.00
Letermovir 710312-77-9 C34H47N11O9S2 7 suppliers Inquiry

Similar articles

IF:4.1

Capmatinib: First Approval.

ACS Chemical Neuroscience Sohita Dhillon,etc Published: 1 July 2020
IF:3.4

Sodium Thiosulfate: Pediatric First Approval.

Pediatric Drugs Sohita Dhillon,etc Published: 1 March 2023
IF:3.4

Letermovir for cytomegalovirus prophylaxis

Australian Prescriber Published: 24 April 2019